Section Arrow
APLM.NASDAQ
- Apollomics Inc
Quotes are at least 15-min delayed:2026/08/11 17:33 EDT
After Hours
Last
 17
-1.16 (-6.39%)
Bid
16.7
Ask
19
High 18.836 
Low 17 
Volume 331 
Regular Hours (Closed)
Last
 18.16
+0.31 (+1.74%)
Day High 
18.2 
Prev. Close
17.85 
1-M High
26.7099 
Volume 
1.76K 
Bid
16.7
Ask
19
Day Low
18.13 
Open
18.13 
1-M Low
14.21 
Market Cap 
39.20M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 17.49 
20-SMA 17.95 
50-SMA 17.42 
52-W High 42.12 
52-W Low 3.659 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-7.57/-0.65
Enterprise Value
39.63M
Balance Sheet
Book Value Per Share
-1.45
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
8.50M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
MREOMereo BioPharma Group plc0.3055+0.0331+12.15%-- 
After Hours 0.329 +0.0235 +7.69%
TENXTenax Therapeutics1.62+0.245+17.82%-- 
After Hours 1.63 +0.01 +0.62%
PDSBPDS Biotechnology Corp0.2568-0.4743-64.87%-- 
After Hours 0.2539 -0.0029 -1.13%
ABCLAbCellera Biologics9.76+0.42+4.50%-- 
After Hours 9.34 -0.42 -4.30%
DRMADermata Therapeutics Inc1.08-0.04-3.57%-- 
After Hours 1.49 +0.41 +37.96%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specificE-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.